anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Sparkline

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 22,963
Current window 14,341-14,370
Pages 766
Rows per page 30
Arc: Sparklineclear collectionreset all
18 30 60

Arc

14,341-14,370 of 22,963

filter-aware
22
The slide uses a wave-like visual to represent market size, with specific dollar amounts associated with different disease categories.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
23
Immix Biopharma | Investor Presentation Deck | 57 slidesImmix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
24
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
25
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
26
The slide uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
27
The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
28
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
29
The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management interventions.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
31
The slide uses a step-wise process diagram to illustrate dose escalation.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
32
The slide features a scientific illustration of cellular structures, likely representing the drug's mechanism of action or target environment.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
33
Includes scientific diagrams of molecular pathways and efficacy data charts.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
34
Slide contains three distinct charts comparing IMX-110 against standard of care and other combinations in mouse models.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
35
Includes a process diagram illustrating the mechanism of action of IMX-110 in turning cold tumors hot.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
36
Includes Kaplan-Meier survival curves and bioluminescence imaging of tumor activity.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
37
Immix Biopharma | Investor Presentation Deck | 57 slidesImmix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
38
Includes waterfall charts and longitudinal patient response plots. Source note provided at bottom.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
39
The slide uses a bubble chart to map clinical trials and a table to summarize drug performance metrics, highlighting low efficacy and high toxicity.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
40
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a small sample size (n=4).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
41
The slide uses a process flow diagram to show trial progression for two distinct treatment arms.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
42
Immix Biopharma | Investor Presentation Deck | 57 slidesImmix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
43
The slide uses a process-flow layout to connect platform capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
44
The slide uses a '3 Pillars' framework to explain the platform foundation, followed by a product-specific breakdown.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
45
Includes technical diagrams of the drug delivery mechanism and comparative survival data.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
46
Includes two sets of charts: tumor volume over time and survival curves. References specific dosing schedules and study parameters.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
47
Includes detailed scientific diagrams of the drug mechanism and clinical trial results.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
48
Immix Biopharma | Investor Presentation Deck | 57 slidesImmix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
49
The slide is divided into two sections: ImmixBio Clinical Advisory Board (top) and Select Nexcella Scientific Advisory Board (bottom).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
50
Immix Biopharma | Investor Presentation Deck | 57 slidesImmix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
51
The slide is organized into two rows, one for each company's board members, featuring headshots, names, titles, and company logos.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit